Casi Pharmaceuticals, INC. (CASIF) SEC Filings — 2024

Filings

• CASI Pharma's CID-103 Faces FDA Clinical Hold — 6-K · Dec 26, 2024
• CASI Pharma Receives Evomela License Termination Notice — 6-K · Dec 16, 2024
• CASI Pharmaceuticals Files 6-K with Press Release — 6-K · Nov 15, 2024
• Casi Pharmaceuticals, INC. SC 13G/A Filing — SC 13G/A · Oct 29, 2024
• CASI Pharmaceuticals Announces Senior Management Changes — 6-K · Sep 12, 2024
• CASI Pharmaceuticals Files August 2024 6-K Report — 6-K · Aug 16, 2024
• Wei-Wu He Amends CASI Pharma Stake — SC 13D/A · Aug 12, 2024
• Casi Pharmaceuticals, INC. SC 13G Filing — SC 13G · Jul 25, 2024
• CASI Pharma Secures Asset Freeze Against Juventas — 6-K · Jul 19, 2024
• CASI Pharmaceuticals Files 6-K for July 2024 — 6-K · Jul 8, 2024
• CASI Pharmaceuticals Files 6-K — 6-K · Jun 27, 2024
• Casi Pharmaceuticals, INC. SC 13G Filing — SC 13G · Jun 20, 2024
• Casi Pharmaceuticals, INC. SC 13G/A Filing — SC 13G/A · Jun 11, 2024
• CASI Pharmaceuticals Files 6-K Report — 6-K · May 15, 2024
• CASI Pharmaceuticals Files 6-K Report — 6-K · Apr 8, 2024
• CASI Pharmaceuticals Files 6-K, Notes Name Change — 6-K · Mar 28, 2024
• CASI Pharmaceuticals, Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 28, 2024
• CASI Pharmaceuticals Faces Nasdaq Delisting — 6-K · Mar 13, 2024
• CASI Pharmaceuticals Files February 2024 6-K Report — 6-K · Feb 29, 2024
• CASI Pharma CCO Fuqiang Zhang Resigns; No Immediate Replacement Planned — 6-K · Feb 12, 2024
• CASI Pharma Appoints Huang Hai as Global CCO & China GM — 6-K · Jan 30, 2024
• Panacea Venture Amends CASI Pharma Stake on Jan 25 — SC 13G/A · Jan 26, 2024